BidaskClub Lowers Amphastar Pharmaceuticals (AMPH) to Strong Sell

Amphastar Pharmaceuticals (NASDAQ:AMPH) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Tuesday.

Other equities analysts also recently issued research reports about the company. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. Raymond James Financial downgraded Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price objective on the stock. in a research report on Thursday, November 9th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Amphastar Pharmaceuticals in a research report on Sunday, September 17th. BMO Capital Markets upped their price objective on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a “market perform” rating in a research report on Friday, November 10th. Finally, Needham & Company LLC upped their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $19.50.

Shares of Amphastar Pharmaceuticals (NASDAQ AMPH) opened at $18.03 on Tuesday. Amphastar Pharmaceuticals has a twelve month low of $12.05 and a twelve month high of $19.95. The firm has a market capitalization of $828.94, a price-to-earnings ratio of 120.40, a P/E/G ratio of 1.27 and a beta of 1.69. The company has a current ratio of 3.08, a quick ratio of 1.86 and a debt-to-equity ratio of 0.13.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The company had revenue of $57.90 million for the quarter, compared to analyst estimates of $57.23 million. During the same quarter in the prior year, the firm posted $0.14 EPS. Amphastar Pharmaceuticals’s quarterly revenue was down 9.8% compared to the same quarter last year. equities analysts forecast that Amphastar Pharmaceuticals will post -0.03 earnings per share for the current fiscal year.

In other news, Director Stephen B. Shohet sold 7,862 shares of the stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $18.04, for a total transaction of $141,830.48. Following the transaction, the director now owns 31,978 shares of the company’s stock, valued at approximately $576,883.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO William J. Peters sold 3,026 shares of the stock in a transaction on Friday, October 13th. The stock was sold at an average price of $18.56, for a total value of $56,162.56. The disclosure for this sale can be found here. Insiders sold a total of 92,060 shares of company stock worth $1,716,956 in the last ninety days. 11.10% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP bought a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth $400,000. Argent Capital Management LLC grew its position in shares of Amphastar Pharmaceuticals by 102.6% during the 3rd quarter. Argent Capital Management LLC now owns 121,275 shares of the company’s stock worth $2,167,000 after buying an additional 61,425 shares in the last quarter. Cornerstone Capital Management Holdings LLC. grew its position in shares of Amphastar Pharmaceuticals by 1.8% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 283,200 shares of the company’s stock worth $5,060,000 after buying an additional 5,000 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Amphastar Pharmaceuticals by 17.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock worth $27,844,000 after buying an additional 226,271 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Amphastar Pharmaceuticals by 11.6% during the 3rd quarter. Nordea Investment Management AB now owns 129,046 shares of the company’s stock worth $2,306,000 after buying an additional 13,439 shares in the last quarter. 44.14% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.com-unik.info/2018/01/09/bidaskclub-lowers-amphastar-pharmaceuticals-amph-to-strong-sell.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit